Skip to content
value.today

Entera Bio Ltd.

Total raised
$2 M
1 round on record
Latest round
$2 M
Oct 2017
First round on record
Oct 2017
Today
Went public
See the company page

Entera Bio Ltd. is listed today as Entera Bio Ltd.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Entera Bio Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2026$275 MPrivate placement after listing$250 million to $1 billion

Entera Bio Ltd.: Private sale, Jul 2026

Investors in this round

53 investors had bought by the notice of Aug 12, 2026: 53 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$275 M of $275 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Pre-Funded Warrants, and underlying Ordinary Shares
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$13,748,625
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Dana Yaacov-Garbeli · Executive Officer · Chief Financial Officer
  • Miranda Toledano · Executive Officer, Director · Chief Executive Officer
  • Geno J. Germano · Director · Chairman of the Board
  • Haya Taitel · Director
  • Sean J. Ellis · Director
  • Steven D. Rubin · Director
  • Yonatan Malca · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Canaccord Genuity LLC (CRD 000001020) · New York, New YorkSold in all US states
  • LifeSci Capital, LLC (CRD 000168404) · New York, New YorkSold in all US states
  • Cantor Fitzgerald & Co. (CRD 000000134) · New York, New YorkSold in all US states
  • Guggenheim Securities, LLC (CRD 000040638) · New York, New YorkSold in all US states
  • Evercore Group L.L.C. (CRD 000042405) · New York, New YorkSold in AK, AL, AR, AZ, CA, CO, CT, DC, FL, GA, IL, IN, KS, KY, LA, MA, MD, MI, MO, MT, NC, NH, NJ, NY, OH, OK, OR, PA, PR, RI, SC, TX, VA, WA, WI, WV
  • Leerink Partners LLC · Boston, MassachusettsSold in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY

Remarks in the notice

  • On the amounts: “Offering amount (rounded) reflects an aggregate of 122,961,215 Ordinary Shares and 11,842,695 Pre-Funded Warrants”

Signed by Dana Yaacov-Garbeli, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 12, 2026. Read the notice at the SEC.

equity, optionsSEC
Dec 2023$7 MPrivate placement after listing$2 to $10 million

Entera Bio Ltd.: Private sale, Dec 2023

Investors in this round

52 investors had bought by the notice of Jan 2, 2024: 52 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Units, each Unit consisting of one ordinary share and one warrant to purchase one ordinary share(includes underlying ordinary shares issuable upon exercise)
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$534,060
Finders' fees
$75,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Arthur Santora · Executive Officer · Chief Medical Officer
  • Dana Yaacov-Garbeli · Executive Officer · Chief Financial Officer
  • Hillel Galitzer · Executive Officer · Chief Operating Officer
  • Miranda Toledano · Executive Officer, Director · Chief Executive Officer
  • Gerald Lieberman · Director · Chairman of the Board of Directors
  • Gerald M. Ostrov · Director
  • Haya Taitel · Director
  • Roger Garceau · Director
  • Ron Mayron · Director
  • Sean Ellis · Director
  • Yonatan Malca · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Network 1 Financial Securities Inc. (CRD 13577) · Red Bank, New JerseySold in all US states, and outside the US

Remarks in the notice

  • On fees: “Sales Commission to Network 1 includes cash fee plus warrants to purchase 487,496 ordinary shares of Issuer. Finders Fees to a non-U.S. finder includes cash fee and warrants to purchase 179,640ordinary shares for non-U.S. sales only.”

Signed by Dana Yaacov-Garbeli, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 2, 2024. Read the notice at the SEC.

equity, optionsSEC
Dec 2019$14 MPrivate placement after listing$10 to $50 million

Entera Bio Ltd.: Private sale, Dec 2019

Investors in this round

52 investors had bought by the notice of Dec 26, 2019: 52 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$472,300
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Limited Liability Company, incorporated in Israel

People named in the notice

  • Adam Gridley · Executive Officer, Director
  • Arthur Santora · Executive Officer
  • Dana Yaacov · Executive Officer
  • Hillel Galitzer · Executive Officer
  • Miranda Toledano · Executive Officer
  • Phillip Schwartz · Executive Officer, Director
  • Roger Garceau · Executive Officer, Director
  • Faith Charles · Director
  • Gerald Lieberman · Director
  • Gerald Ostrov · Director
  • Yonatan Malca · Director
  • Zeev Bronfeld · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • GP Nurmenkari, Inc. (CRD 153480) · broker-dealer GP Nurmenkari, Inc. (CRD 153480) · Norwalk, ConnecticutSold in CA, FL, GA, IL, MI, NJ, NY, PA, TX

Remarks in the notice

  • On fees: “Warrants were also issued, of which the value cannot be determined”

Signed by Adam Gridley, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 26, 2019. Read the notice at the SEC.

equity, optionsSEC
Oct 2017$2 MNo. 1$2 to $10 million

Entera Bio Ltd.: Raise no. 1, Oct 2017

Investors in this round

30 investors had bought by the notice of Oct 19, 2017: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $7 M offered; $5 M still to sell
Smallest investment taken
$9,996
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$202,294
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Phillip Schwartz · Executive Officer, Director
  • Chaim M. Davis · Director
  • David M. Ben Ami · Director
  • Gerald Lieberman · Director
  • Luke M. Beshar · Director
  • Roger M. Garceau · Director
  • Yonatan M. Malca · Director
  • Zeev M. Bronfeld · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • GP NURMENKARI INC. (CRD 153480) · New York, New YorkSold in CA, FL, IL, MA, MD, NH, NJ, NY, OH, TX

Remarks in the notice

  • On fees: “Sales commission relates to cash fee of 10% from $2,022,944.28 gross proceeds. Amounts do not include additional compensation in the form of warrants for the purchase of up to 10% of the number of equity securities sold.”

Signed by Phillip Schwartz, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 19, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Entera Bio Ltd. chose not to state its revenue in its newest notice of a funding round (Aug 2026).

    SEC Form D · Aug 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2026

That is all the official record says: Entera Bio Ltd. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Entera Bio Ltd. are on record.

Investors#

No investor of Entera Bio Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 30 investors.

Largest shareholders today

Institutions holding Entera Bio Ltd. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Entera Bio Ltd.
NameRoleNamed in
Dana Yaacov-GarbeliChief Financial OfficerAug 2026
Miranda ToledanoChief Executive OfficerAug 2026
Arthur SantoraChief Medical OfficerJan 2024
Hillel GalitzerChief Operating OfficerJan 2024
Adam GridleyExecutive officerDec 2019
Dana YaacovExecutive officerDec 2019
Phillip SchwartzExecutive officerDec 2019
Roger GarceauExecutive officerDec 2019
Geno J. GermanoChairman of the BoardAug 2026
Haya TaitelDirectorAug 2026
Miranda ToledanoChief Executive OfficerAug 2026
Sean J. EllisDirectorAug 2026
Steven D. RubinDirectorAug 2026
Yonatan MalcaDirectorAug 2026
Gerald LiebermanChairman of the Board of DirectorsJan 2024
Gerald M. OstrovDirectorJan 2024
Roger GarceauDirectorJan 2024
Ron MayronDirectorJan 2024
Sean EllisDirectorJan 2024
Adam GridleyDirectorDec 2019
Faith CharlesDirectorDec 2019
Gerald OstrovDirectorDec 2019
Phillip SchwartzDirectorDec 2019
Zeev BronfeldDirectorDec 2019
Chaim M. DavisDirectorOct 2017
David M. Ben AmiDirectorOct 2017
Luke M. BesharDirectorOct 2017
Roger M. GarceauDirectorOct 2017
Yonatan M. MalcaDirectorOct 2017
Zeev M. BronfeldDirectorOct 2017

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.